TScan Therapeutics signs separation agreements with CFO Amello and CMO Louis

TScan Therapeutics, Inc.

CFO Jason A. Amello and CMO Chrystal Louis, M.D., MPH, will terminate employment on the earlier of Nov. 1, 2026 or the start of other employment.
Amello remains entitled to previously disclosed termination payments plus an $85,000 milestone-based lump sum under the November 2025 retention program.
Louis remains entitled to previously disclosed termination payments plus a $125,000 milestone-based lump sum under the 2025 Retention Program.
During the transition, each executive’s base salary and applicable employee benefits will continue until the earlier of Nov. 1, 2026 or new employment.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.